Clinical trial

A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC

NCT06671379

Study summary

ClinicalTrials.gov

A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC

Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE3

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention SHR-A2009 monotherapy Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention platinum-based dual-agent chemotherapy Find medicine records · Find other trials using this name

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2024-11-29

PhasePHASE3

Conditions

Non-small Cell Lung Cancerverified · MONDO: non-small cell lung carcinoma

Interventions

SHR-A2009 monotherapyDRUG

platinum-based dual-agent chemotherapyDRUG

Sponsors & collaborators

Suzhou Suncadia Biopharmaceuticals Co., Ltd.lead sponsor

Mapped research locations

GuangzhouGuangdong, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06671379 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.